Printer Friendly

Generalized vaccinia 2 days after smallpox revaccination.

To the Editor: Hospital and public health personnel are currently receiving smallpox vaccination in a national effort to increase preparedness for a possible deliberate release of smallpox (1). Generalized vaccinia (GV) is a typically self-limited adverse event following vaccination (incidence 23.4-238.2 cases per million primary vaccinees and 1.2-10.8 cases per million revaccinees) (2,3).

We report the clinical course and laboratory diagnosis of GV in a 37-year-old woman with a history of at least one uncomplicated childhood inoculation that left a vaccination scar. She was revaccinated on March 12, 2003. Before revaccination, the patient reported no contraindications to vaccination and denied any conditions that typically weaken the immune system (including HIV/AIDS, leukemia, lymphoma, other cancers, radiation, chemotherapy, organ transplant, post-transplant therapy, immunosuppressive medications, severe autoimmune disease, and primary immune deficiency). The patient also confirmed that she did not have a skin disease or a history of eczema or atopic dermatitis, nor was she pregnant or allergic to a vaccine component.

On March 14, some 44 hours after vaccination, the patient reported headache, chills, pruritus, chest pain (described as chest "heaviness"), recurrent vomiting, and maculopapular lesions. The lesions, characterized by the patient as "mosquito bites," first appeared on the face, then the legs, and then the trunk and upper extremities. Maximum oral temperature was 37.7 [degrees] C. Over the next 4 days, approximately 30 pustules developed, several of which began to drain. Nausea persisted, and the patient had a stiff neck and recurring chest tightness, but physical examination, echocardiography, electrocardiography, and chest radiography results were within normal limits. By March 25, the patient's lesions had all scabbed, the scabs had fallen off, and she felt well enough to return to work. Pustular material obtained on March 18 from two unroofed lesions on the shoulder (Figure) and back tested positive at the Wadsworth Center-Axelrod Institute, New York State Department of Health, for vaccinia virus DNA by a TaqMan (Applied Biosystems, Foster City, CA) real-time polymerase chain reaction assay provided by the Laboratory Response Network, Centers for Disease Control and Prevention. The presence of ortho-poxvirus was confirmed by electron microscopy of lesion fluid.

This case is the first report of a laboratory-confirmed case of GV among recent civilian vaccinees and is notable for the GV occurrence in a revaccinee. GV was not reported among 132,656 military personnel recently revaccinated (4). A single case of GV in a revaccinee among 38,514 recent civilian vaccinations (5) yields a ratio that exceeds the rate in revaccinees observed in earlier reports and the difference would be even greater if civilians who received primary vaccinations were excluded.

This laboratory confirmation of GV demonstrates the potential of laboratory testing to determine the cause of a post-vaccination rash. Possible cases of GV in earlier surveillance efforts represented a mixed group of rashes, some of uncertain etiology (6). This patient's clinical course is notable for the onset of GV 2 days after vaccination, as compared to a mean of 9 days (range 1-20 F) after (generally primary) vaccination (2) and suggests that viremia can occur quickly after vaccination.


We thank the patient, as well as our colleagues Peter Drabkin, Christina Egan, Cassandra Kelly, Debra Blog, Stephen Davis, William Samsonoff, Kimberly A. Musser, and Jill Taylor.

James R. Miller, * Nick M. Cirino, * and Edward F. Philbin ([dagger])

* New York State Department of Health, Albany, New York, USA; and ([dagger]) Albany Medical College, Albany, New York, USA


(1.) Wharton M, Strikas RA, Harpaz R. Rotz LD, Schwartz B, Casey CG, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;52:(No.RR-7):1-16,

(2.) Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.

(3.) Neff JM, Levine RH, Lane JM, Ager EA, Moore H, Rosenstein BJ, et al. Complications of smallpox vaccination United States 1963. II. Results obtained by tour statewide surveys. Pediatrics 1967;39:916-23.

(4.) Grabenstein JD, Winkenwerder W. US military smallpox vaccination program Experience. JAMA 2003;289:3278-82.

(5.) Centers for Disease Control and Prevention. Smallpox Vaccination Program Status by State [cited October 9, 2003]. Available from: URL: od/oc/media/spvaccin.htm

(6.) Neff JM, Lane JM, Pert JH, Moore R, Millar JD, Henderson DA. Complications of smallpox vaccination. I. National survey in the United States, 1963. N Engl J Med 1967;276:125-32.

Address for correspondence: James R. Miller, New York State Department of Health, Bureau of Communicable Disease Control, Coming Tower Rm 678, Albany, NY 12237, USA; fax: 518-486-2249; email: jrm
COPYRIGHT 2003 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Letters
Author:Philbin, Edward F.
Publication:Emerging Infectious Diseases
Article Type:Letter to the Editor
Date:Dec 1, 2003
Previous Article:Influenza pandemic preparedness.
Next Article:Salmonella enterica Serovar Enteritidis, Japan.

Related Articles
Smallpox: clinical and epidemiologic features.
Aftermath of a hypothetical smallpox disaster.
[Translation of front cover text] Use of Vaccine Has Spread from Osaka to Edo (Tokyo) for the Benefit of Mankind.
Smallpox vaccine policy: the national debate. (Health Policy Update).
Smallpox vaccination begins in U.S.--precautions needed.
Smallpox: could a deadly disease--declared eradicated on Earth--come back to haunt humans as a bioweapon? (Life Science Infectious Viruses).
Risks and benefits of preexposure and postexposure smallpox vaccination. (1).
Flow cytometry and T-cell response monitoring after smallpox vaccination.
Frequency of revaccination against smallpox.
Surveillance and control measures during smallpox outbreaks.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters